Share This Article:

In vivo immunomodulatory effects of antipsychotics on inflammatory mediators: A review

Abstract Full-Text HTML Download Download as PDF (Size:335KB) PP. 551-565
DOI: 10.4236/abb.2012.324072    3,894 Downloads   7,520 Views   Citations


Background: Substantial evidence demonstrates the presence of an inflammatory syndrome in schizophrenia, which is manifested by increased peripheral levels of interleukin-6 (IL-6), soluble interleukin-2 receptor (sIL-2R), and interleukin-1 receptor antagonist (IL-1RA). Unfortunately, the immunomodulatory effects of antipsychotics on peripheral cytokine levels remain poorly understood. Objectives: The objectives of the current systematic review are to determine if antipsychotics have anti-inflammatory effects in patients with schizophrenia-spectrum disorders and to examine the relationships between antipsychotic-induced cytokine changes and drug response or common side effects. Method: A systematic search was performed in the electronic databases PubMed and EMBASE. Results: We identified 39 studies measureing the effects of 8 antipsychotics on 13 inflammatory mediators and 4 cytokine receptors. This literature suggests that antipsychotics (especially clozapine) consistently decrease peripheral interleukin-2 (IL-2) levels and increase sIL-2R and soluble tumor-necrosis factor (sTNF-R) receptor levels. Changes in IL-2/sIL- 2R levels seem to correlate with changes in positive symptoms. Preliminary results suggest that antipsychotics decrease interferon-γ (IFN-γ) and transforming growth factor-β (TGF-β) levels, and increase interleukin-4 (IL-4) levels. Antipsychotic-induced changes in IL-6, C-reactive protein (CRP) and tumor-necrosis factor-α (TNF-α) have been linked with common antipsychotic side effects (metabolic, fever). Discussion: Despite significant clinical heterogeneity across studies, this review has evidenced that antipsychotics can produce both anti- and pro-inflammatory effects that may partially contribute to drug response and drug-induced side effects. In the future, a better understanding of the molecular mechanisms of action of antipsychotics on inflammatory mediators will help to identify novel therapeutic strategies as well as novel biomarkers of treatment response and of drug-induced side effects in schizophrenia.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Tourjman, V. , Koué, M. , Kouassi, E. and Potvin, S. (2012) In vivo immunomodulatory effects of antipsychotics on inflammatory mediators: A review. Advances in Bioscience and Biotechnology, 3, 551-565. doi: 10.4236/abb.2012.324072.


[1] Seeman, P. (2002) Atypical antipsychotics: mechanism of action. Can. J. Psychiatry, 47, 27-38.
[2] Rogers, D.P.; Goldsmith, C.A. (2009) Treatment of schizophrenia in the 21st century: beyond the neurotransmitter hypothesis. Expert Rev. Neurother., 9, 47-54. doi:10.1586/14737175.9.1.47
[3] Levin, S.Z., Rabinowitz, J., Ascher-Svanum, H., Faries, D.E. and Lawson, A.H. (2011) Extent of attaining and maintaining symptom remission by antipsychotic medication in the treatment of chronic schizophrenia: evidence from the CATIE study. Schizophr. Res., 133, 42-46. doi:10.1016/j.schres.2011.09.018
[4] Drzyzga, L., Obuchowicz, E., Marcinowska, A. and Herman, Z.S. (2006) Cytokines in schizophrenia and the effects of antipsychotic drugs. Brain Behav. Immun., 20, 532-545. doi:10.1016/j.bbi.2006.02.002
[5] Miller, B.J., Buckley, P., Seabolt, W., Mellor, A. and Kirkpatrick B. (2011) Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry, 70, 663–671. doi:10.1016/j.biopsych.2011.04.013
[6] Kato, T.A., Monji, A., Mizoguchi, Y., Hashioka, S., Horikawa, H., Seki, Y., Kasai, M., Utsumi, H. and Kanba, S. (2011) Anti-inflammatory properties of antipsychotics via microglia modulations: are antipsychotics a “fire extinguisher” in the brain of schizophrenia? Mini Rev. Chem., 11, 565-574.
[7] Baptista, T. and Beaulieu, P. (2002) Are leptin and cytokines involved in body weight gain during treatment with antipsychotic drugs? Can. J. Psychiatry, 47, 742-749.
[8] Kluge, M., Schuld, A., Schacht, A., Himmerich, H., Dalal, M.A., Wehmeier, P.M., Hinze-Selch, D., Kraus, T., Dittmann, R.W. and Pollmacher, T. (2009) Effets of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever. Psychoneuroendocrinology, 34, 118-128. doi:10.1016/j.psyneuen.2008.08.016
[9] Igue, R., Potvin, S., Bah, R., Stip, E., Bouchard, R.H., Lipp, O., Gendron, A. and Kouassi. E. (2011) Soluble interleukin-2 receptor levels correlated with positive symptoms during quetiapine treatment in schizophrenia-spectrum disorders. Progr. Neuro-Psychopharmacol. Biol. Psychiatry, 35, 1695-1698. doi:10.1016/j.pnpbp.2011.05.011
[10] Monji, A., Kato, T.A., Mizoguchi, Y., Horikawa, H., Seki, Y., Kasai, M., Yamauchi, Y., Yamada, S. and Kanba, S. (2011) Neuroinflammation in schizophrenia especially focused on the role of microglia. Prog. Neuropsychopharmacol. Biol. Psychiatry, Epub ahead of print. doi:10.1016/j.pnpbp.2011.12.002
[11] Müller, N., Myint, A.M. and Schwarz, M.J. (2011) Kynurenine pathway in schizophrenia: pathophysiological and therapeutic aspects. Curr. Pharm. Des., 17, 130-136. doi:10.2174/138161211795049552
[12] Potvin, S., Stip, E., Sepehry, A.A., Gendron, A., Bah, R. and Kouassi, E. (2008,) Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol. Psychiatry, 63, 801-808. doi:10.1016/j.biopsych.2007.09.024
[13] Crespo-Facorro, B., Carrasco-Marín, E., Pérez-Iglesias, R., Pelayo-Terán, J.M., Fernandez-Prieto, L., Leyva-Cobián, F. and Vázquez-Barquero, J.L. (2008) Interleukin-12 plasma levels in drug-naive patients with a first episode of psychosis: Effects of antipsychotic drugs. Psychiatry Res., 158, 206-216. doi:10.1016/j.psychres.2006.08.005
[14] Cortese, M. (1959) Research on the influence of chlorpromazine on immune processes. Riv. Ist. Sieroter. Ital., 34, 198-193.
[15] Mengozzi, M., Fantuzzi, G., Faggioni, R., Marchant, A., Goldman, M., Orencole, S., Clark, B.D., Sironi, M., Benigni, F. and Ghezzi, P. (1994) Chlorpromazine specifically inhibits peripheral and brain TNF production, and up-regulates IL-10 production, in mice. Immunology, 82, 207-210.
[16] Song, C., Lin, A., Kenis, G., Bosman, E. and Maes, M. (2000) The immunosuppressive effects of clozapine and haloperidol: enchanced production of the interleukin-1 receptor antagonist. Schizophr. Res., 42, 157-164. doi:10.1016/S0920-9964(99)00116-4
[17] Sugino, H., Futamura, T., Mitsumoto, Y., Maeda, K. and Marunaka, Y. (2009) Atypical antipsychotics suppress production of proinflammatory cytokines and up-regulate interleukin-10 in lipolysaccharide-treated mice. Prog. Neuropsychopharmacol. Biol. Psychiatry, 33, 303-307. doi:10.1016/j.pnpbp.2008.12.006
[18] Maes, M., Meltzer and H.Y.; Bosman, E. (1994) Immune-inflammatory makers in schizophrenia: comparison to normal controls and affects of clozapine. Acta Psychiatr. Scand., 89, 349-351. doi:10.1111/j.1600-0447.1994.tb01527.x
[19] Pollmacher, T., Hinze-Selch, D. and Mullington, J. (1996) Effect of clozapine on plasma cytokine and soluble cytokine receptor Levels. J. Clin. Psychopharmacol., 16, 403-409. doi:10.1097/00004714-199610000-00011
[20] Pae, C.U., Yoon, C.H., Kim, T.S., Kim, J.J., Park, S.H., Lee, C.U., Lee, S.J., Lee, C. and Paik, I.H. (2006) Antipsychotic treatment may alter T-helper (TH) 2 arm cytokines. Int. Immunopharmacol., 6, 666-671. doi:10.1016/j.intimp.2005.10.004
[21] Baptista, T., Sandia, I., Lacruz, A., Rangel, N., De Mendoza, S., Beaulieu, S., Contreras, Q., Galeazzi, T. and Vargas, D. (2007a) Insulin counter-regulatory factors, fibrinogen and C-reactive protein during olanzapine administration: effects of the antidiabetic metformin. Int. Clin. Psychoparmacol., 22, 69-76. doi:10.1097/YIC.0b013e32801182e6
[22] Pollmacher, T., Hinze-Selch, D., Fenzel, T., Kraus, T., Schuld, A. and Mullington, J. (1997) Plasma levels of cytokines and soluble cytokine receptors during treatment with haloperidol. Am. J. Psychiatry, 154, 1763-1765.
[23] McAllister, C.G., Van Kammen, D.P., Rehn, T.J., Miller, A.L., Kelley, M.E., Yao, J. and Peters, J.L. (1995) Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status. Am. J Psychiatry, 152, 1291-1297.
[24] Hinze-Selch, D. and Pollmacher, T. (2001) In vitro cytokine secretion in individuals with schizophrenia: results, confounding factors, and implications for future research. Brain Behav. Immun., 15, 282-318. doi:10.1006/brbi.2001.0645
[25] Akandji, A.O., Ohaeri, J.U., Al-Ahammri, S. and Fatania, H.R. (2009) Association of blood levels of C-reactive protein with clinical phenotypes in Arab schizophrenic patients. Psychiatry Res., 169, 56-61. doi:10.1016/j.psychres.2008.06.010
[26] Akiyama, K. (1999) Serum levels of soluble IL-2 receptor a, IL-6 and IL-1 receptor antagonist in schizophrenia before and during neuroleptic administration. Schizophr. Res., 37, 97-106. doi:10.1016/S0920-9964(98)00140-6
[27] Baptista, T., Davila, A., El Fakih, Y., Uzcategui, E., Rangel, N.N., Olivares, Y., Galeazzi, T., Vargas, D., Pena, R., Marquina, D., Villarroel, V., Teneud, L. and Beaulieu, S. (2007b) Similar frequency of abnormal correlation between sérum leptin levels and BMI before and after olanzapine treatment in schizophrenia. Int. Clin. Psychoparmacol., 22, 205-211. doi:10.1097/YIC.0b013e328080ca44
[28] Baptista, T., Rangel, N., Fernandez, V., Carrizo, E., El Fakih, Y., Uzcategui, E., Galeazzi, T., Gutierrez, M.A., Servigna, M., Davila, A., Uzcategui, M., Serrano, A., Connell, L., Beaulieu, S. and de Baptista, EA. (2007c) Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial. Schizophr. Res., 93, 99-108. doi:10.1016/j.schres.2007.03.029
[29] Diaz, F.J., Perez-Iglesias, R., Mata, I., Martinez-Garcia, O., Vasquez-Barquero, J.L., De Leon, J. and Crespo-Facorro, B. (2010) Possible effects of some antipsychotic drugs on C-reactive protein in a drug-naive psychotic sample. Schizophr. Res., 121, 207-212. doi:10.1016/j.schres.2010.06.002
[30] Fernandez-Egea,E., Miller, B., Garcia-Rizo, C., Bernardo, M. and Kirkpatrick, B. (2011) Metabolic Effects of Olanzapine in patients With Newly Diagnosed Psychosis. J. Clin. Psychopharmacol., 31, 154-159. doi:10.1097/JCP.0b013e31820fcea3
[31] Frommberger, U.H., Bauer, J., Haselbauer, P., Fraulin, A., Riemann, D. and Berger M. (1997) Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur. Arch. Psychiatry Clin. Neurosci., 247, 228-233. doi:10.1007/BF02900219
[32] Graham, K.A., Cho, H., Brownley, K.A. and Joyce, B.H. (2008) Early treatment-related changes in diabetes and cardiovascular disease risk markers in first episode psychosis subjects. Schizophr. Res., 101, 287-294. doi:10.1016/j.schres.2007.12.476
[33] Henderson, D.C., Fan, X., Copeland, P.M., Sharma, B., Borba, C.P., Boxill, R., Freudenreich, O., Cather, C., Evins, A.E. and Goff, D.C. (2009) Aripiprazole added to overweight and obese olanzapine-Treated schizophrenia patients. J. Clin. Psychopharmacol., 29, 165-169. doi:10.1097/JCP.0b013e31819a8dbe
[34] Hinze-Selch, D., Deuschle, M., Weber, B., Heuser, I. and Pollmacher, T. (2000) Effect of coadministration of clozapine and fluvoxamine versus clozapine monotherapy on blood cell counts, plasma levels of cytokines and body weight. Psychopharmacology, 149, 163-169. doi:10.1007/s002139900351
[35] Hori, H., Yoshimura, R., Yamada, Y., Ikenouchi, A., Mitoma, M., Ida, Y. and Nakamura, J. (2007) Effects of olanzapine on plasma levels of catecholamine metabolites, cytokines, and brain-derived neurotrophic factor in schizophrenic patients. Int. Clin. Psychopharmacol., 22, 21-27. doi:10.1097/YIC.0b013e3280103593
[36] Kim, Y.K., Myint, A.M., Verkerk, R., Scharpe, S, Steinbusch, H. and Leonard, B. (2009) Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients. Neuropsychobiology, 59, 123-129. doi:10.1159/000213565
[37] Kim, Y.K., Myint, A.M., Lee, B.H., Han, C.S., Lee, H.J., Kim, D.J. and Leonard. B.E. (2004) Th1, Th2, and Th3 cytokine alteration in schizophrenia. Progr. Neuro-Psyphopharmacol. Biol. Psychiatry, 28, 1129-1134. doi:10.1016/j.pnpbp.2004.05.047
[38] Kim, Y.K,, Suh, I.B., Kim, H., Han, C.S., Choi, S.H. and Licinio, J. (2002) The plasma levels of interleukin-12 in schizophrenia, major depression, and bipolar mania: effects of psychotropic drugs. Mol. Psychiatry, 7, 1107-1114. doi:10.1038/
[39] Kim, D.J., Kim, W., Yoon, S.J., Go, H.J., Choi, B.M., Jun, T.Y. and Kim, Y.K. (2001) Effet of risperidone on serum cytokines, Intern. J. Neurosci., 111, 11-19. doi:10.3109/00207450108986549
[40] Kim, Y.K.; Kim, L.; Lee, M.S. (2000) Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics, Schizophr. Res., 44, 165-175. doi:10.1016/S0920-9964(99)00171-1
[41] Lin, C.C., Chang, C.M., Cahng, P.Y. and Huang, T.L. (2011) Increased Interleukin-6 Level in Taiwanese Schizophrenic Patients. Chang. Gung. Med. J., 34, 375-381.
[42] Loffler, S., Loffler-Ensgraber, M., Fehsel, K. and Klimke, A. (2010) Clozapine therapy raises serum concentrations of high sensitive C-reactive protein in schizophrenic patients. Int. Clin. Psychopharmacol., 25, 101-106. doi:10.1097/YIC.0b013e32833643fd
[43] Lü, L.X., Guo, S.Q., Chen, W., Li, Q., Cheng, J. and Guo, J.H. (2004) Effect of clozapine and risperidone on serum cytokine levels in patients with first-episode paranoid schizophrenia. Di Yi Jun Yi Da Xue Xue Bao., 24, 1251-1254.
[44] Maes, M., Chiavetto, L.B., Bignotti, S., Battisa Tura, G.J., Pioli, R., Boin, F., Kenis, G., Bosmans, E., De Jongh, R. and Altamura, C.A. (2002) Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and stimulatory effects of clozapine on serum leukemia inhibitory factor receptor. Schizophr. Res., 54, 281-291. doi:10.1016/S0920-9964(00)00094-3
[45] Maes, M., Chiavetto, L.B., Bignotti, S., Battisa Tura, G.J., Pioli, R., Boin, F., Kenis, G., Bosmans, E., De Jongh, R., Lin, A., Racagni, G. and Altamura, C.A. (2000) Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics. Eur. Neuropsychopharmacol., 10, 119-124. doi:10.1016/S0924-977X(99)00062-0
[46] Maes, M., Bosmans, E., Kenis, G., De Jong, R., Smith, R.S. and Meltzer, H.Y. (1997) In vivo immunomodulatory effects of clozapine in schizophrenia, Schizophr. Res., 26, 221-225. doi:10.1016/S0920-9964(97)00057-1
[47] Maes, M., Bosmans, E., Calabrese, J., Smithe, R. and Meltzer, H.Y. (1995) Interleukin-2 and Interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J. Psychiat. Res., 26, 141-152. doi:10.1016/0022-3956(94)00049-W
[48] Meyer, J.M., McEvoy, J.P., Davis, V.G., Goff, D.C., Nasrallah, H.A., Davis, S.M., Hsiao, J.K., Swartz, M.S., Stroup, T.S. and Lieberman, J.A. (2009) Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness Study. Biol. Psychiatry, 66, 1013-1022. doi:10.1016/j.biopsych.2009.06.005
[49] Monteleone, P., Fabrazzo, M., Tortorella, A. and Maj, M. (1997) Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: effects of clozapine treatment, Psychiatry Res., 71, 11-17. doi:10.1016/S0165-1781(97)00036-X
[50] Müller, N.; Ulmschneider, M.; Scheppach, C.; Schwarz, M.J.; Ackenheil, M.; Moller, H.J.; Gruber, R.; Riedel M. (2004) COX-2 inhibition as a treatment approach in schizophrenia: Immunological considerations and clinical effects of celecoxib add-on therapy. Eur. Arch. Psychiatry Clin. Neurosci., 254, 14-22. doi:10.1007/s00406-004-0478-1
[51] Müller, N.; Empl, M.; Riedel, M.; Schwarz, M.; Ackenheil, M. (1997) Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci., 247, 308-313. doi:10.1007/BF02922260
[52] Pollmacher, T., Hinze-Selch, D., Mullington, J. and Holsboer, F. (1995) Clozapine-induced increase in plama levels of soluble interleukin-2 receptors. Arch. Gen. Psychiatry, 52, 877-878. doi:10.1001/archpsyc.1995.03950220087016
[53] Sarandol, A., Kirli, S., Akkaya, C., Ocak, N., Eroz, E. and Sarandol, E. (2007) Coronary artery disease risk factors in patients with schizophrenia: effects of short term antipsychotic treatment. J. Psychopharmacol., 21, 857-863. doi:10.1177/0269881107077609
[54] Sirota, P., Meiman, M., Herschko, R. and Bessler, H. (2005) Effect of neuroleptic administration on serum levels of soluble IL-2 receptor-alpha and IL-1 receptor antagonist in schizophrenic patients. Psychiatry Res., 134, 151-159. doi:10.1016/j.psychres.2004.04.012
[55] Song, X.Q., Lv, L-X, Li W-Q, Hao Y-H and Zhao J-P. (2009) The interaction of nuclear factor-kappa B and cytokines is associated with schizophrenia. Biol. Psychiatry, 65, 481–488. doi:10.1016/j.biopsych.2008.10.018
[56] Zhang, X., Zhou, D.F., Qi, L.Y., Chen, S., Cao, L.Y., Chen, D.C., Xiu, M.H., Wang, F., Wu, G.Y., Lu, L., Kosten, T.A. and Kosten, T.R. (2009) Superoxide dismutase and cytokines in chronic patients with schizophrenia: association with psychopathology and response to antipsychotics. Psychopharmacology, 204, 177-184. doi:10.1007/s00213-008-1447-6
[57] Rapaport, M.H. and Lohr, J.B. (1994) Serum-soluble interleukin-2 receptors in neuroleptic-naive schizophrenic subjects and in medicated schizophrenic subjects with and without tardive dyskinesia. Acta Psychiatr. Scand., 90, 311-315. doi:10.1111/j.1600-0447.1994.tb01599.x
[58] Zalcman, S.S., Patel, A., Mohla, R., Zhu, Y. and Siegel, A. (2012) Soluble cytokine receptors (sIL-2Ra, sIL-2Rb) induce subunit-specific behavioral responses and accumulate in the cerebral cortex and basal forebrain. PLoS ONE, 7, e36316. doi:10.1371/journal.pone.0036316
[59] Bradley, J.R. (2008) TNF-mediated inflammatory disease. J. Pathol., 214, 149-160. doi:10.1002/path.2287
[60] Borst, S.E. (2004) The role of TNF-alpha in insulin resistance. Endocrine, 23, 177-182. doi:10.1385/ENDO:23:2-3:177
[61] Chen, X., Xun, K., Chen, L. and Wang, Y. (2009) TNF-alpha, a potent lipid metabolism regulator. Cell Biochem. Funct., 27, 407-416. doi:10.1002/cbf.1596
[62] Iosif, R.E., Ekdahl, C.T., Ahlenius, H., Pronk, C.J., Bonde, S., Kokala, Z., Jacobsen, S.E. and Lindvall, O. (2006) Tumor necrosis factor receptor 1 is a negative regulator of progenitor proliferation in adult hippocampal neurogenesis. J. Neurosci., 26, 9703-9712. doi:10.1523/JNEUROSCI.2723-06.2006
[63] Bast, T. (2011) The hippocampal learning-behavior translation and the functional significance of hippocampal dysfunction in schizophrenia. Curr. Opin. Neurobiol., 21, 492-501. doi:10.1016/j.conb.2011.01.003
[64] Hebel, K., Rudolph, M., Kosak, B., Chang, H.D., Butzmann, J. and Brunner-Weinzierl, M.C. (2011) IL-1beta and TGF-beta act antagonistically in induction and differentially in propagation of human proinflammatory precursor CD4+ T cells. J. Immunol., 187, 5627-5635. doi:10.4049/jimmunol.1003998
[65] Regateiro, F.S., Howe, D., Nolan, K.F., Agorogiannis, E.I., Greaves, D.R., Cobbold, S.P. and Waldmann, H. (2011) Generation of anti-inflammatory adenosine by leucocytes is regulated by TGF-beta. Eur. J. Immunol., 41, 2955-2965. doi:10.1002/eji.201141512
[66] Tsianakas, A., Varga, G., Barczyk, K., Bode, G., Nippe, N., Kran, N., Roth, J., Luger, T.A., Ehrchen, J. and Sunderkoetter, C. (2012) Induction of an anti-inflammatory human monocyte subtype is a unique property of glucocorticoids, but can be modified by IL-6 and IL-10. Immunobiology, 217, 329-335. doi:10.1016/j.imbio.2011.10.002
[67] Sanjabi, S., Zenewicz, L.A., Kamanaka, M. and Flavell, R.A. (2009) Anti-inflammatory and pro-inflammatory roles of TGF-beta, IL-10, and IL-22 in immunity and autoimmunity. Curr. Opin. Pharmacol., 9, 447-453. doi:10.1016/j.coph.2009.04.008
[68] Rummel-Kluge, C., Komossa, K., Schwarz, S., Hunger, H., Schmid, F., Lobos, C.A., Kissling, W., Davis, J.M. and Leucht, S. (2010) Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr. Res., 23, 225-233. doi:10.1016/j.schres.2010.07.012
[69] Devaraj, S., Singh, U. and Jialal, I. (2009) Human C-reactive protein and the metabolic syndrome. Curr. Opin. Lipid. 20, 182-189. doi:10.1097/MOL.0b013e32832ac03e
[70] Juge-Aubry, C.E., Somm, E., Giusti, V., Pernin, A., Chicheportiche, R. and Verdumo, C. (2003) Adipose tissue is a major source of interleukin-1 receptor antagonist: upregulation in obesity and inflammation. Diabetes, 52, 1104-1110. doi:10.2337/diabetes.52.5.1104
[71] Sommer, I.E., de Witte, L., Begemann, M. and Kahn, R.S. (2012) Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? a meta-analysis. J. Clin. Psychiatry, 73, 414-419. doi:10.4088/JCP.10r06823
[72] Reale, M., Patruno, A., De Litis, M.A., Pesce, M., Felaco, M., Di Giannantonio, M., Di Nicola, M. and Grilli, A. (2011) Dysregulation of chemo-cytokine production in schizophrenic patients versus healthy controls. BMC Neurosci., 12, 13. doi:10.1186/1471-2202-12-13
[73] Reyes-García, M. G. and García-Tamayo, F. (2009) A neurotransmitter system that regulates macrophage pro-inflammatory functions. J. Neuroimmunology, 216, 20–31. doi:10.1016/j.jneuroim.2009.06.024
[74] Pacheco, R., Riquelme, E. and Kalergis, A. M. (2010) Emerging evidence for the role of neurotransmitters in the modulation of T cell responses to cognate ligands. Central Nervous System Agents in Medicinal Chemistry, 10, 65-83.
[75] Levine, S.J. (2008) Molecular mechanisms of soluble cytokine receptor generation. J. Biol. Chem., 283, 14177-14181. doi:10.1074/jbc.R700052200
[76] Steptoe, A., Hamer, M. and Chida, Y. (2007) The effects of acute psychological stress on circulating inflammatory factors in humans: a review and meta-analysis. Brain Behav. Immun., 21, 901-912. doi:10.1016/j.bbi.2007.03.011
[77] Wolf, J.M., Rohleder, N., Bierhaus, A., Nawroth, P.P. and Kirschbaum, C. (2009) Determinants of the NF-kappaB response to acute psychosocial stress in humans. Brain Behav. Immun., 23, 742-749. doi:10.1016/j.bbi.2008.09.009
[78] Zhang, X.Y., Zhou, D.F., Cao, L.Y., Wu, G.Y. and Shen, Y.C. (2005) Cortisol and cytokines in chronic and treatment-resistant patients with schizophrenia: association with psychopathology and response to antipsychotics. Neuropsychopharmacology, 30, 1532-1538. doi:10.1038/sj.npp.1300756
[79] Gadek-Michalska, A., Tadeusz, J., Rachwalska, P., Spyrka, J. and Bugajski, J. (2011) Effect of prior stress on interleukin-1beta and HPA axis responses to acute stress. Pharmacol. Rep., 63, 1393-1403.
[80] Black, P.H. (2003) The inflammatory response is an integral part of the stress response: implications for atherosclerosis, insulin resistance, type II diabetes and metabolic syndrome X. Brain Behav. Immun., 17, 350-364. doi:10.1016/S0889-1591(03)00048-5
[81] Gnacinska, M., Malgorzewicz, S., Lysiak-Szydlowska, W. and Sworczak, K. (2010) The serum profile of adipokines in overweight patients with metabolic syndrome. Endokrynol. Pol., 61, 36-41.
[82] Edwards, C. (2012) Sixty years after Hench--corticosteroids and chronic inflammatory disease. J. Clin. Endocrinol. Metab., 2012, 97, 1443-1451. doi:/10.1210/jc.2011-2879
[83] Toda, N. and Nakanishi-Toda, M. (2011) How mental stress affects endothelial function. Pflugers Arch., 462, 779-794. doi:10.1007/s00424-011-1022-6
[84] Dunn, A.J. (2006) The effects of cytokines and infections on brain neurochemistry. Clin. Neurosci. Res., 6, 52-68. doi:10.1016/j.cnr.2006.04.002
[85] Connor, T.J., Song, Leonard, B.E., Merali, Z. and Anisman, H. (1998) An assessment of the effects of central interleukin-1beta, -2, -6, and tumor necrosis factor-alpha administration on some behavioural, neurochemical, endocrine and immune parameters in the rat. Neuroscience, 84, 923-933. doi:10.1016/S0306-4522(97)00533-2

comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.